Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group

Minimal residual disease (MRD) as a marker of antileukemic drug efficacy is being used to assess risk status and, in some cases, to adjust the intensity of therapy. Within known prognostic categories, the determinants of MRD are not known. We measured MRD by flow cytometry at day 8 (in blood) and at...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Davies, Stella M., Borowitz, Michael J., Rosner, Gary L., Ritz, Kristin, Devidas, Meenakshi, Winick, Naomi, Martin, Paul L., Bowman, Paul, Elliott, James, Willman, Cheryl, Das, Soma, Cook, Edwin H., Relling, Mary V.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2008
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2265447/
https://ncbi.nlm.nih.gov/pubmed/18182569
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-09-114082
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky